
    
      The study is designed to estimate the maximum change in QTcF (change from baseline) between
      placebo and multiple-dose tivantinib. A tivantinib oral dose of 360 mg BID has been selected
      for this study because this is the highest dose currently being evaluated in clinical
      studies.
    
  